Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (681-690 of 713) with videos related to

Pageof 72
Sort By:
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 2014
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimensRonald M Sobecks, Jose F Leis, Robert Peter Gale, et al.
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Cell|March 10, 2010
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blastsAnna M Eiring, Jason G Harb, Paolo Neviani, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
Pageof 72

Showing results (681-690 of 713) with videos related to

Sort By:
Pageof 72
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 2014
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimensRonald M Sobecks, Jose F Leis, Robert Peter Gale, et al.
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Cell|March 10, 2010
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blastsAnna M Eiring, Jason G Harb, Paolo Neviani, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Haematologica|May 30, 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisFranck E Nicolini, Amr R Ibrahim, Simona Soverini, et al.
Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.
Pageof 72